Author Archives: Julian Upton

Every Tenth New European Drug Developed in Finland

The number of drugs developed in Turku, Finland and granted marketing authorizations this year now stands at three, with a fourth expected to follow. The FDA has granted market authorization for the IUD Skyla, developed by Bayer and intended for women who have not given birth, and Hormos Medical’s Ophena for postmenopausal symptoms. The European […]
Posted in Europe, Global | Tagged , , , , | Leave a comment

EMA Sets Budget and Priorities for 2014, Promotes Transparency

In a bid to improve transparency in 2014, the European Medical Agency’s December Management Board Meeting cleared the way for the publication of the agendas and minutes of the Agency’s Committee for Medicinal Products for Human Use (CHMP), Committee for Medicinal Products for Veterinary Use (CVMP) and Committee for Advanced Therapies (CAT). This week the EMA […]
Posted in Europe, Global, Regulatory | Tagged , , , , | Leave a comment

New Funding and Approval Pathways Prove Popular

By Rita Peters, Editorial Director, BioPharm International. Compared to other manufacturing and technology industries, the bio/pharmaceutical industry has one of the longest product development timelines. The research, development, testing, and regulatory review process typically extends for more than a decade, often exhausting the financial resources and commitment of investors. For patients with unmet medical needs, the […]
Posted in Biotech, FDA, Guest Blog, Regulatory | Tagged , , , , , , | Leave a comment

Shutdown Stalls US–EU Trade Agreement Talks

Another temporary casualty of the US government shutdown are the negotiations surrounding the US and Europe’s mooted free trade agreement. The second round of the Transatlantic Trade and Investment Partnership (T-TIP) talks were due to start this week in Brussels, Belgium, but following last Tuesday’s closedown of non-essential US operations, trade representative Michael Froman told […]
Posted in Europe, Global | Tagged , , , , | Leave a comment

Teva Joins Top 10, “Face” of Big Pharma Changing

Teva’s accession to the exclusive group that is the Pharma Top 10 is further proof, according to IMS Health, that branded pharma needs to renounce its product-protected past and embrace the patient-led, specialty-focused future. As the first non-western, non-innovative-core company to enter pharma’s global Top 10, according to IMS Health research, Teva’s rise to prominence […]
Posted in Global, Strategy | Tagged , , , | 1 Comment
  • Categories

  • Meta